E. Lederman

MediPharm brought an action against Hexo for unpaid invoices totaling $9,802,032.78 under a cannabis resin supply agreement.

Hexo counterclaimed against MediPharm for breach of contract and bad faith, and against Peter Hwang, a former director of the acquired company, for breach of fiduciary duty.

MediPharm and Hwang brought motions for summary judgment.

The court granted the motions, finding no genuine issue for trial.

Hexo failed to adduce evidence of bad faith by MediPharm or self-dealing by Hwang, whose decisions were protected by the business judgment rule.

Hexo was ordered to pay the outstanding invoices.

The applicant purchased two commercial condominium units from the respondent developer.

The purchase price was to be adjusted based on the 'actual gross area' of the units, calculated in accordance with the BOMA 1996 Standard.

The applicant argued the price should be based only on the net usable area, while the respondent argued it must include a gross-up for floor and building common areas.

The court dismissed the application, finding that the contract's explicit reference to the BOMA 1996 Standard objectively demonstrated the parties' intention to include the proportionate share of common areas in the calculation of the purchase price.